Is imetelstat useful for people abivev60

The short version: imetelstat shows real, dose-dependent clinical benefit for roughly one in three to one in two older transfusion-dependent patients, but it comes with near-universal toxicities that require careful management.

Imetelstat is a telomerase inhibitor. For people over 60 with lower-risk myelodysplastic syndromes (LR-MDS) who need regular red blood cell transfusions and have stopped responding to standard treatments, the evidence from 2025–2026 teaches two things clearly. The positive finding: about 42% of patients achieve at least 8 weeks of transfusion independence (no need for transfused blood), and about 33% sustain that for 24 weeks or longer, with hemoglobin rises averaging nearly 7 g/dL [3, 5]. Patients whose bone marrow is hit hardest by the drug — a 50% or greater drop in platelets — had the best responses, with a 33% rate of 24-week transfusion independence versus only 7% in those whose platelets fell less [5]. This suggests the marrow suppression is on-target: the drug is doing what it is supposed to.

The cost of that benefit is predictable. 69% of patients experienced severe (Grade 3 or higher) neutropenia, and 61% had severe thrombocytopenia, both appearing around week 4 and resolving within about 2 weeks [5]. Infections near those low-neutrophil windows were uncommon (4%), and serious bleeding near low-platelet windows was rare (under 1%), but 37% needed growth-factor shots and 19% needed platelet transfusions to get through it [5]. Every single patient in the phase III trial (178 of 178) had at least one adverse event [5].

The data come from Geron-funded post-hoc and pooled analyses of the IMerge trial [3, 5]. That is manufacturer-sponsored evidence, and the sample sizes for subgroup breakdowns are small. The phase III trial had no true placebo arm — patients were all sick enough to need transfusions and had already failed prior drugs — so the placebo effect is partly controlled but not eliminated. Overall survival data were not mature at the cutoff date [3]. The mechanism by which imetelstat works — crippling a cancer cell's ability to maintain its telomeres — is well-supported at the bench level across multiple cancer types [1, 4], but some tumors can switch to an alternative telomere-maintenance pathway (ALT) and become resistant [2].

For the older patient with LR-MDS who is transfusion-dependent, imetelstat offers a meaningful chance of reducing transfusion frequency for months, with a roughly one-in-six chance of a full year off transfusions. The side-effect profile is severe but transient and manageable with monitoring. The longer-term cancer risk from suppressing telomerase in normal stem cells is not well-studied, and the durability of benefit beyond one year is not known from these data.

My call: imetelstat is useful for roughly a third of older transfusion-dependent LR-MDS patients, with a severe but transient side-effect window that requires a hematologist comfortable handling cytopenias. Confidence: moderate — the results are consistent and biologically plausible, but the evidence is manufacturer-sponsored, the survival data are immature, and the long-term risks are uncharted.